Aytu Biopharma, Inc.
AYTU
$2.17
-$0.04-1.81%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.71% | 31.57% | -13.48% | -6.98% | -52.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.71% | 31.57% | -13.48% | -6.98% | -52.52% |
| Cost of Revenue | 37.84% | 54.09% | 31.12% | -3.98% | -70.90% |
| Gross Profit | -7.22% | 23.60% | -26.14% | -8.08% | -40.47% |
| SG&A Expenses | -10.30% | -8.64% | -2.96% | -12.93% | -32.95% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.33% | -0.32% | -22.93% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.07% | 4.25% | 6.39% | -10.51% | -46.45% |
| Operating Income | 277.29% | 278.94% | -112.02% | 83.16% | -112.85% |
| Income Before Tax | -666.38% | 316.07% | -72.69% | 120.05% | -3.26% |
| Income Tax Expenses | -48.04% | -123.42% | -136.28% | -- | -- |
| Earnings from Continuing Operations | -488.51% | 272.20% | 7.43% | 114.63% | -37.48% |
| Earnings from Discontinued Operations | 105.00% | 109.02% | 114.66% | 158.89% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -329.24% | 238.34% | 458.18% | 118.15% | -87.91% |
| EBIT | 277.29% | 278.94% | -112.02% | 83.16% | -112.85% |
| EBITDA | 61.57% | 1,976.67% | -80.53% | 31.25% | -75.70% |
| EPS Basic | -255.16% | 224.80% | 422.06% | 116.40% | -38.57% |
| Normalized Basic EPS | -30,161.76% | 326.16% | 9.27% | 127.58% | -112.32% |
| EPS Diluted | -255.16% | 139.60% | -523.75% | 89.33% | -38.57% |
| Normalized Diluted EPS | -30,161.76% | 269.07% | -21.07% | 118.39% | -112.32% |
| Average Basic Shares Outstanding | 20.85% | 10.86% | 11.14% | 10.69% | 35.61% |
| Average Diluted Shares Outstanding | 20.85% | 48.27% | 53.78% | 65.99% | 35.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |